Preclinical work by researchers from Danish Orphazyme ApS has demonstrated that targeting heat-shock protein 70 (Hsp70) could alleviate a number of different lysosomal storage diseases, a group of several dozen rare to ultra-rare disorders united by mutations in proteins that lead to problems with cellular waste disposal.